What is a stock summary page? Click here for an overview.
Business Description
Immunocore Holdings PLC
NAICS : 541714
SIC : 2834
ISIN : US45258D1054
Share Class Description:
IMCR: ADRDescription
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 1.2 | |||||
| Debt-to-EBITDA | -14.63 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.3 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 93.3 | |||||
| 3-Year EBITDA Growth Rate | 46.6 | |||||
| 3-Year EPS without NRI Growth Rate | 39.2 | |||||
| 3-Year Book Growth Rate | 10.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.88 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.14 | |||||
| 9-Day RSI | 48.98 | |||||
| 14-Day RSI | 48.74 | |||||
| 3-1 Month Momentum % | 1.92 | |||||
| 6-1 Month Momentum % | -4.73 | |||||
| 12-1 Month Momentum % | -53.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.38 | |||||
| Quick Ratio | 4.36 | |||||
| Cash Ratio | 3.87 | |||||
| Days Inventory | 590.58 | |||||
| Days Sales Outstanding | 69.84 | |||||
| Days Payable | 2621.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | -25.93 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.12 | |||||
| Operating Margin % | -22.72 | |||||
| Net Margin % | -16.47 | |||||
| FCF Margin % | 6.73 | |||||
| ROE % | -13.99 | |||||
| ROA % | -5.42 | |||||
| ROIC % | -72.79 | |||||
| 3-Year ROIIC % | 1565.8 | |||||
| ROC (Joel Greenblatt) % | -76.55 | |||||
| ROCE % | -4.5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.78 | |||||
| PB Ratio | 4.07 | |||||
| Price-to-Tangible-Book | 4.07 | |||||
| Price-to-Free-Cash-Flow | 73.83 | |||||
| Price-to-Operating-Cash-Flow | 58.72 | |||||
| EV-to-EBIT | -32.46 | |||||
| EV-to-Forward-EBIT | -10.75 | |||||
| EV-to-EBITDA | -37.08 | |||||
| EV-to-Forward-EBITDA | -8.23 | |||||
| EV-to-Revenue | 3.53 | |||||
| EV-to-Forward-Revenue | 2.89 | |||||
| EV-to-FCF | 52.49 | |||||
| Price-to-GF-Value | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 5.23 | |||||
| Price-to-Net-Cash | 8.55 | |||||
| Earnings Yield (Greenblatt) % | -3.08 | |||||
| FCF Yield % | 1.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMCR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunocore Holdings PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 310.202 | ||
| EPS (TTM) ($) | -1.02 | ||
| Beta | 0.83 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 45.19 | ||
| 14-Day RSI | 48.74 | ||
| 14-Day ATR ($) | 1.605773 | ||
| 20-Day SMA ($) | 29.42875 | ||
| 12-1 Month Momentum % | -53.28 | ||
| 52-Week Range ($) | 27.19 - 66 | ||
| Shares Outstanding (Mil) | 50.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunocore Holdings PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunocore Holdings PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immunocore Holdings PLC Frequently Asked Questions
What is Immunocore Holdings PLC(IMCR)'s stock price today?
The current price of IMCR is $29.32. The 52 week high of IMCR is $66.00 and 52 week low is $27.19.
When is next earnings date of Immunocore Holdings PLC(IMCR)?
The next earnings date of Immunocore Holdings PLC(IMCR) is 2025-05-08 Est..
Does Immunocore Holdings PLC(IMCR) pay dividends? If so, how much?
Immunocore Holdings PLC(IMCR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers